Influence of Probiotic Supplementation on Health Status of the Dogs: A Review

Bhagavathi Sundaram Sivamaruthi 1,2, Periyanaina Kesika 1,* and Chaiyavat Chaiyasut 1,*

1 Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand; sivamaruthi.b@cmu.ac.th
2 Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand
* Correspondence: p.kesika@gmail.com (P.K.); chaiyavat@gmail.com (C.C.); Tel.: +66-53-944-340 (P.K. & C.C.)

Abstract: Most commonly, pet dogs suffer from gastrointestinal (GI) diseases due to careless eating behaviors, such as eating food other than dog food; excess or insufficient nutrient intake of food leading to malnutrition, which could be harmful to dogs; a lack of digestive enzymes; food intolerance or allergies; infections; and/or breed-related hypersensitivities. Probiotics are live microorganisms that deliver health benefits to the host when administered in an adequate amount. The possible mechanism behind probiotics’ beneficial effects could be their positive regulation of the host’s intestinal microbiota. Probiotics are reported to have therapeutic properties against canine GI and other diseases. The most suitable dosages and applications of probiotics have not been evaluated extensively. The present review summarizes current knowledge regarding the benefits of probiotics and the changes in canine microbiota during probiotic interventions. This literature review provides clinical evidence for probiotics’ beneficial effects in preventing or treating canine ill-health conditions. Based on current knowledge, subsequent researchers could develop or improve probiotics-based canine pharmacological products.

Keywords: canine; probiotics; microbiota; Lactobacillus

1. Introduction

Companion dogs need nutritional care to maintain good health [1]. Dogs are fed with foods supplemented with appropriate nutrients such as choline, vitamins (E, B5, B3, B2, B1, K, B6, A, B9, B12, D), and minerals (calcium, potassium, phosphorus, magnesium, etc.) in addition to the dietary components, such as proteins, carbohydrates, fats, and fibers [1]. Malnutrition can occur due to an excess or a deficiency in nutrient intake, which could be harmful to dogs [2]. The nutritional requirements of each dog can differ based on the dog’s breed, size, developmental stage, and level of activity [1]. Even if companion animals are fed with nutritionally balanced diets to maintain good health, any differences in their normal microbiota can facilitate illness upon exposure to harmful environmental influences and pathogens [3,4]. The supplementation of probiotics positively regulates the microbiota of the host and improves their health [5–7]. The joint Food and Agriculture Organization (FAO) of the United Nations and World Health Organization (WHO) defines the term “probiotics” as “live microorganisms which when administered in adequate amounts confer a health benefit on the host” [8]. The term “probiotics” refers to live microbes (isolated from different sources, such as gut commensals, fermented foods, and any other source) that have been characterized and evidenced in adequate controlled studies to have a health beneficial effect, and their safety has been verified. Even though microbial components,
dead microbes, and microbial products exhibit health beneficial effects, they should not be considered as probiotics [9]. The ideal characteristics of probiotics include being non-pathogenic to the host, the ability to tolerate low pH levels and high concentrations of bile acids in the gastrointestinal environment, and the ability to proliferate in the gut by adhering to the intestinal epithelium. For economically viable production, the probiotics should also preferably have the ability to grow well on inexpensive media and tolerate manufacturing, transportation, and storage processes [10,11]. Probiotic supplementation aids in maintaining gut health by preventing or controlling pathogens in the gastrointestinal tract and promoting the population of favorable gastrointestinal tract microflora. The modes of action of probiotics might be strain-specific [11]. Since the supplementation of probiotics is not universally safe and effective in humans [12], probiotics should also be used with caution in companion animals until the limitations of probiotics usage in companion animals are found. Probiotics have been reported to have several health benefits in humans, such as facilitating dental health [13], aiding in cancer management [14], exerting cholesterol-lowering abilities [15], controlling diabetes mellitus [16], and exhibiting immune-stimulating properties [17]. Generally, probiotics that are beneficial to humans are considered to be safe, but canine-derived probiotics could be used safely for canine animals [18].

The intervention of a probiotic-supplemented diet can protect dogs from various health effects. The supplementation of probiotics has been used for the alleviation or prevention of atopic dermatitis [19,20] and treatment of gastrointestinal diseases, such as diarrheal diseases [21–25] in companion animals.

An updated literature review on the role of probiotic supplementation in the health status of domestic dogs is necessary to contribute to the development of new probiotics-based nutraceuticals. This review summarizes the impact of probiotics interventions on domestic dogs and the changes that occur in the microbiota of dogs upon probiotic intervention.

Scientific evidence was collected from Scopus, Web of Science, PubMed, and Google Scholar using the keywords “Probiotics” and “Dogs”. Blinded controlled clinical trials (published from 1998 to February 2021) that were published with details such as a probiotic name, probiotic dose (CFU), and the details of animals used in the study were selected manually and used to prepare the manuscript.

2. Characterization of the Microbiota in Dogs

The microbiomes of humans and pet animals have similarities [26], and the microbiota play a critical role in health and diseases among pet animals [27,28]. Previous bacterial-culture-based studies showed that healthy dogs contain a 10^2 to 10^{11} CFU/g bacterial load in their gastrointestinal (GI) tracts. Recently, high-throughput DNA sequencing techniques were implemented to determine the microbiomes of canines [29]. Current molecular methods revealed that the microbial loads of healthy dogs can range from 10^{12} to 10^{14} [30–32]. García–Mazarro et al. [33] reported that Firmicutes was the predominant phylum, followed by Actinobacteria, Proteobacteria, and Bacteroidetes, which were identified in the fecal microbiome of healthy dogs. Fusobacteria and Acidobacteria were the least abundant phylum compared to the other identified phyla in the fecal microbiome of healthy dogs [33]. Jha et al. [34] reported the same set of phyla as the predominant one found in the fecal samples of dogs [34].

The microbial load of each segment in the GI tract varies based on that section’s physiological functions [35,36]. For instance, the small intestine is rich in aerobic and facultative anaerobic bacteria, while the colon harbors anaerobic bacteria [35]. Individual variations in the microbiota of different intestinal compartments (such as higher diversity indices for the colon, rectum than those of duodenum, jejunum, and ileum within individual dogs) may also be present, and these variations must be taken into account to explain the microbiota of healthy dogs [36]. The results can fluctuate based on the sequencing method and depth of the study. Some studies showed that Firmicutes (abundant in duodenum, jejunum, ileum,
and colon), Fusobacteria (abundant in ileum, and colon), Bacteroidetes (abundant in ileum, and colon) [37], Proteobacteria (abundant in duodenum [37,38], jejunum, ileum [38], and rectum [37]), and Actinobacteria [37] are the primary phyla identified in the GI tract of the dog microbiota [37,38].

Clostridia is the most abundant bacterial class. Clostridium clusters XI (more abundant in the small intestine) and XIVa (more abundant in the colon) are the dominant clusters of Clostridia [37–39]. In addition to Clostridia, Bacilli (genera Streptococcus and Lactobacillus) and Erysipelotrichi (genera Turicibacter, Catenibacterium, and Coprobacillus) are the dominant classes belonging to Firmicutes [39].

Prevotella, Bacteroides [39,40], Sutterella [40], SMB53, Enterococcus, Fusobacterium [34], and, Megamonas [34,39] are the most abundant genera among the gut microbial populations in dogs.

3. Health Benefits of Probiotic Supplementation in Healthy Dogs

3.1. Microbiota Changes and Other Benefits in Healthy Dogs upon Probiotic Supplementation

The supplementation of Enterococcus faecium NCIB 10415 (derived from healthy adult canine feces) (9.2 \( \times \) \( 10^9 \) CFU/dog/day) for 18 days reduced the fecal count of Clostridium spp. in healthy dogs. E. faecium NCIB 10415 lowered the fecal count of Campylobacter spp. and Salmonella spp. in a few healthy dogs and insignificantly increased the fecal count of Campylobacter spp. and Salmonella spp. in the majority of the healthy dogs, indicating that E. faecium NCIB 10415 was not effective in inhibiting the growth of Campylobacter spp. and Salmonella spp. in the majority of healthy dogs. Although the study results suggested the beneficial effects of E. faecium NCIB 10415 in inhibiting the pathogenic Clostridium spp., the effects of probiotics should be evaluated with caution [41] (Table 1).

Biagi et al. [42] studied the effects of Lactobacillus animalis LA4 (derived from healthy adult canine feces) on the composition and metabolism of dog intestinal microbiota under both in vitro and in vivo conditions. The in vitro evaluation showed that upon exposure of L. animalis LA4 to adult dog fecal cultures, L. animalis LA4 increased the count of Lactobacillus and reduced the Clostridium perfringens count. Moreover, LA4 increased the level of lactic acid in fecal cultures. LA4 reduced the ammonia concentration under in vitro conditions, while fecal concentration of ammonia was not influenced by LA4 under in vivo conditions. When healthy dogs (n = 9 adult) were fed with L. animalis LA4 (10^9 CFU/g; 0.5 g per dog per day) for 10 days, the count of Lactobacillus was increased, and the enterococci count was reduced. The in vivo evaluations of Lactobacillus count also supported the findings of the in vitro experiments. The in vivo results showed that the strain LA4 could withstand the gastrointestinal environment and proliferate in the intestines of the studied adult dogs [42].

The supplementation of Bacillus amyloliquefaciens CECT 5940 and E. faecium CECT 4515 (0.2 g of a probiotic blend = 1 \( \times \) \( 10^8 \) CFU of each probiotic strain per dog per day; each strain = 5 \( \times \) \( 10^8 \) CFU per gram food) in the food of healthy dogs for 39 days did not affect the nutrient digestibility coefficients, fecal scores, or microbiota, whereas reduction was observed in the pathogenic clostridia count in the feces of healthy dogs administered probiotics. This study revealed that the supplementation of CECT 5940 and CECT 4515 reduced the pathogenic clostridia count without influencing food digestibility in healthy dogs [43].

A probiotic preparation (daily dose: 1 g of probiotic supplement/10 pounds of body weight) containing Lactobacillus (>64 \( \times \) \( 10^9 \) CFU/g), Bifidobacterium (30 \( \times \) \( 10^9 \) CFU/g), and Bacillus species (24 \( \times \) \( 10^9 \) CFU/g) was orally administered to healthy female dogs for 14 or 28 days. The study results showed that probiotic supplementation orally for 14 or 28 days did not increase the vaginal lactic acid bacteria (LAB) in the healthy dogs [44].

Park et al. [45] investigated the effect of the supplementation of Queso Blanco cheese containing Bifidobacterium longum KACC 91563 (5 \( \times \) \( 10^8 \) CFU/10 g cheese/kg of body weight/day) on intestinal microbiota and short chain fatty acids (SCFA) in healthy companion dogs. The fecal samples were collected at different stages such as before intake of cheese (week −2 and 0), during cheese intake (week 4 and 8), and after intake of cheese
The microbiota analysis revealed that the cheese containing KACC 91563 supplementation effectively reduced the Enterobacteriaceae and *Clostridium* count and increased *Bifidobacterium* in the feces of the companion dogs. The results showed that KACC 91563 intervention for eight weeks reduced the harmful bacterial load and increased the beneficial microbes in the dog intestine. Moreover, the SCFA, such as acetic and propionic acid levels, were raised during probiotic supplementation [45]. Similarly, Queso Blanco cheese containing *B. longum* KACC 91563 (5 × 10⁸ CFU/10 g cheese/day) altered the fecal microbiota by effectively increasing the *Bifidobacterium* and decreasing *C. perfringens*, Enterobacteriaceae, *Collinesella*, *Blautia*, and *Fusobacterium* in healthy beagle dogs. Overall, these results demonstrated that the supplementation of probiotic Queso Blanco cheese could improve the health status of companion dogs [45,46].

A non-medicated milk replacement containing *Bacillus amyloliquefaciens* CECT 5940 (1 × 10⁹ CFU/g dry matter of probiotic product/dog/day) was administered to healthy dogs for 60 days, and the changes in microbiota were assessed. The results revealed that the bacillus count increased, and the coliform count decreased, in the probiotic-supplemented group compared to the control. The stool consistency was not affected by the probiotic supplementation. This study showed that CECT 5940 could survive the gastrointestinal passage and colonize in the dog intestine, further positively altering the intestinal microbial composition [47].

A probiotic food additive comprising *Lactobacillus casei* Zhang, *Lactobacillus plantarum* P-8, and *Bifidobacterium animalis* subsp. *lactis* V9 (equal proportion of 3 probiotic strains in a final concentration of 2 × 10⁹ CFU/g; Dosage: 2 g/day for each young dog; 4 g/day for each training dog; 10 g/day for each elderly dog) was administered to healthy dogs of different age groups (young, training, and an elderly group) for two months. Probiotic supplementation increased the load of *Lactobacillus* spp. and *Faecalibacterium prausnitzii* but decreased the abundance of *Sutterella stercoricanisin* and *Escherichia coli* in the feces of the experimental elderly dogs. Moreover, the induction of cytokines and antibodies was positively regulated in the probiotic-treated group. Two months of probiotic treatment also shifted the gut microbiota of elderly dogs towards the composition of microbiota found in younger dogs at the end of the experimental study. Changes in some microbial species showed a correlation with some immune factors (such as fecal secretory IgA, serum IgG, TNF-α), indicating that probiotic intervention governs the immune system by changing the gut’s microbial composition in dogs [48].

Kefir, a probiotic dairy product (200 mL of kefir/day; Kefir contains LAB (9.32 ± 0.23 log CFU per mL), and yeast (7.12 ± 0.36 log CFU per mL)), was administered orally to healthy dogs (n = 6 adult; 2 females, 4 males) for two weeks, and the changes in microbiota were assessed. The load of *Fusobacteria*, *Clostridiaceae*, *Fusobacteriaceae*, *Ruminococcaceae*, and the *Firmicutes: Bacteroidetes* ratio decreased, whereas quantities of LAB, *Sutterellaceae*, *Prevotellaceae*, and *Selenomonadaceae* and the LAB: *Enterobacteriaceae* ratio increased in the group that consumed kefir. This study revealed that kefir supplementation effectively improved the dogs’ intestinal microbiota, and that kefir could be used as a functional food to improve dogs’ health [49].

*Lactobacillus kefiri* (10⁷ cells per day) was administered to healthy dogs (n = 10) for 30 days. The changes in gut microbiota composition were assessed in the fecal samples of the experimental dogs. The results suggested that the fecal microbiota of the experimental dogs were not influenced upon administration of *L. kefiri* [50].
Table 1. The effects of probiotic supplementation on the health status of healthy dogs.

| Ref. | Model | Probiotic Used | Dose per Animal | Duration | Effect of Probiotic Supplementation |
|------|-------|----------------|----------------|----------|-------------------------------------|
| [41] | Healthy dogs (Probiotic group, n = 12) | Enterococcus faecium NCIB 10415 | 9.2 × 10⁶ CFU/day | 18 days | Reduced the fecal count of Clostridium spp. Not effective in inhibiting the growth of Campylobacter spp. and Salmonella spp. |
| [42] | Healthy dogs (Probiotic group, n = 9) | Lactobacillus animalis LA4 | 10⁹ CFU/g; 0.5 g per day | 10 days | LA4 could withstand the gastrointestinal environment and proliferate in the dog intestines |
| [43] | Healthy dogs (Probiotic group, n = 8; Control group, n = 8) | Bacillus amyloliquefaciens CECT 5940 and E. faecium CECT 4515 | 0.2 g of a probiotic blend = 1 × 10⁹ CFU of each probiotic strain per day | 39 days (probiotic supplementation period); 6 days adaptation period before the supplementation period | Reduced fecal clostridia count |
| [44] | Healthy dogs (Probiotic group 1, n = 23; Probiotic group 2, n = 12) | Lactobacillus, Bifidobacterium, and Bacillus species | Daily dose: 1 g of probiotic supplement/10 pounds of body weight; Lactobacillus (>64 × 10⁶ CFU/g), Bifidobacterium (30 × 10⁶ CFU/g), and Bacillus species (24 × 10⁶ CFU/g) | 14 days (probiotic group 1); 28 days (probiotic group 2) | No increase in the prevalence of vaginal lactic acid bacteria |
| [45] | Healthy dogs (Probiotic group, n = 5; Placebo group, n = 5; Control group, n = 5) | Queso Blanco cheese containing Bifidobacterium longum KACC 91563 | 5 × 10⁶ CFU/10 g cheese/kg of body weight/day | 8 weeks | Reduced the fecal Enterobacteriaceae and Clostridium count |
| [46] | Healthy dogs (Probiotic group, n = 4; Placebo group, n = 4; Control group, n = 4) | Queso Blanco cheese containing Bifidobacterium longum KACC 91563 | 5 × 10⁶ CFU/10 g cheese/day | 8 weeks | Increased the short-chain fatty acids such as acetic and propionic acid levels |
| [47] | Healthy dogs (Probiotic group, n = 4; Control group, n = 4) | Bacillus amyloliquefaciens CECT 5940 | 1 × 10⁹ CFU/g dry matter of probiotic product/day | 30 days (probiotic supplementation period); 6 days adaptation period before the supplementation period | Increased the fecal clostridium count |
| | Healthy dogs (Elderly probiotic group, n = 15; Elderly control group, n = 15; Young probiotic group, n = 12; Young control group, n = 12; Training probiotic group, n = 18; Training control group, n = 18) | Lactobacillus casei Zhang, Lactobacillus plantarum P-8, and Bifidobacterium animalis subsp. lactis V9 | Equal proportions of 3 probiotic strains in a final concentration of 2 × 10⁷ CFU/g; Dosage: 10 g/day (Elderly group); 2 g/day (Young group); 4 g/day (Training group) | 60 days | Increased the fecal load of Lactobacillus spp. and Fecalibacterium prausnitzii and decreased the abundance of Sutterella stercorisimus and Escherichia coli in the elderly dogs. |
| [51] | Healthy dogs (Probiotic group, n = 11) | E. faecium EE3 | 10⁶ CFU/mL | 1 week | Reduced the fecal staphylococci and Pseudomonas load |
| [52] | Healthy dogs (Probiotic group, n = 5; Placebo group, n = 5; Control group, n = 5) | Lactobacillus johnsonii CPN23 or L. acidophilus NCDC15 | 10⁶ CFU per mL; 0.1 mL per kg of body weight | 13 weeks (9 weeks probiotic supplementation period); (next 4 weeks to study the withdrawal effects) | Reduced the plasma glucose levels in the dogs of both probiotic groups |
| | | | | | Superoxide dismutase and glutathione peroxidase activity were higher in L. johnsonii/CPN23-treated dogs |
| [53] | Healthy dogs (Probiotic group, n = 18; Control group, n = 18) | E. faecium SF68 | 5 × 10⁶ CFU/g/day | 14 days | An effective cobalamin reduction was observed during the 28th day (after a 14-day follow-up) |
| [54] | Healthy dogs (Probiotic group, n = 18; Control group, n = 18) | E. faecium SF68 | 5 × 10⁶ CFU/g/day | 14 days | No changes in serum alanine transferase and alkaline phosphatase activity |
| Ref. | Model | Probiotic Used | Dose per Animal | Duration | Effect of Probiotic Supplementation |
|------|-------|----------------|-----------------|----------|-----------------------------------|
| [55] | Healthy dogs (Probiotic group supplemented with two different concentrations of probiotic, n = each 5; Control group, n = 5) | *Weissella cibaria* JW15 | 50 g per day; $3 \times 10^8$ CFU/g or $3 \times 10^9$ CFU/g | 14 days | Decreased the serum TG levels and fecal ammonia emissions in the probiotic group. Improvement of fecal lactobacilli load and serum HDL-C levels |
| [56] | Healthy dogs (Probiotic group, n = 8; Control group, n = 8) | *Bacillus subtilis* and *Bacillus licheniformis* | 3.66 $\times 10^7$ CFU of each bacterial strain/kg of the diet | 20 days | Improved the fecal consistency and reduced the occurrence of fetid feces. Reduced the fecal biogenic amine content, thereby reducing the fecal odor |
| [57] | Healthy dogs (Probiotic group, n = 14; Control group, n = 16) | *L. acidophilus* D2/CSL | $5 \times 10^6$ CFU/g of feed additive; Pre-mixture contains 50 g of feed additive + 9950 g of maltodextrin; 20 g of pre-mixture per day | 35 days (probiotic supplementation period); 7 days adaptation period before the supplementation period | Maintained a perfect body condition score throughout the study. Improved the fecal moisture content |
| [58] | Healthy dogs (n = 15) | *Lactobacillus fermentum* AD1 | $10^8$ CFU | 7 days | Increased the fecal count of lactobacilli and enterococci and, also increased serum level of total lipid and total protein. Reduced the serum glucose level |
| [59] | Healthy dogs (Probiotic group 1, n = 12; Probiotic group 2, n = 11) | *Lactobacillus fermentum* AD1-CCM7421 | Probiotic group 1 (2 g per day; $10^6$ CFU/g of milk powder); Probiotic group 2 (1 g per day; $10^5$ CFU/g of milk powder) | 14 days (Probiotic group 1); 7 days (Probiotic group 2) | Reduced the fecal count of clostridia and increased the total fecal concentration of SCFA such as butyric, formic, succinic, and valeric acid in probiotic group 1. Reduced the fecal count of *Aeromonas sp.*, *E. coli* and *Pseudomonas sp.* in probiotic group 2 |

The administration of *E. faecium* EE3 ($10^9$ CFU per mL) to healthy dogs (n = 11) for one week reduced the fecal staphylococci and *Pseudomonas* load. Most of the dogs showed a reduction in total lipid levels. Cholesterol levels were also impacted in dogs upon probiotic intervention (i.e., probiotic supplementation increased the cholesterol levels to reach physiological level in the dogs those showed low cholesterol values in their blood samples and also decreased the cholesterol levels to reach physiological level in those with high levels). Moreover, the strain EE3 was found in the experimental dogs’ feces after three months of the study. The results showed that EE3 could improve the health condition of healthy dogs [51].

The healthy dogs were administered *Lactobacillus johnsonii* CPN23 or *Lactobacillus acidophilus* NCDC15 ($10^8$ CFU per mL; 0.1 mL per kg of body weight) for nine weeks, and the biochemical profile and antioxidant capacity were assessed. Probiotic supplementation reduced the plasma glucose levels in the dogs of both probiotic groups (each group n = 5) compared to that of the control group (n = 5). There was no change in catalase, reduced glutathione, or glutathione S-transferase levels in the probiotic-treated dogs, while superoxide dismutase and glutathione peroxidase activity were higher in the *L. johnsonii* CPN23-treated dogs [52].

The administration of *E. faecium* SF68 ($5 \times 10^8$ CFU/g/day) for 14 days to healthy dogs (non-hypocobalaminemic breeds; Age = 2–5 years old) (probiotic group, n = 18, 10 females, 8 males) reduced the mean serum cobalamin when compared with the baseline and at day 14. In this study, cobalamin concentration is considered clinically relevant when the reduction is 25% to 30% from the mean baseline concentration of cobalamin (301.7 pg/mL). An effective cobalamin reduction was observed during the 28th day (after a 14-day follow-up). There was a non-significant increase in the serum folate level at day 14; however, this level was reduced at day 28. The canine IBD activity index score was nil for both probiotic...
and control groups during the study. All dogs of both group showed no alterations on the general attitude, appetite, weight, consistency or frequency of feces and there were no adverse effects. The results showed that short-term \( E. \text{faecium} \) SF68 supplementation could reduce the serum cobalamin in healthy dogs \[53\]. The supplementation of \( E. \text{faecium} \) SF68 (5 × 10^8 CFU/g/day) for 14 days was unable to change the liver function (serum alanine transferase and alkaline phosphatase activity) in healthy dogs \[54\].

Adult beagles were supplemented with \( \text{Weissella cibaria} \) JW15 (probiotic strain isolated from kimchi) in two different concentrations (50 g per day; 3.0 × 10^8 CFU/g or 3.0 × 10^9 CFU/g) along with regular food for 14 days. The serum TG levels and fecal ammonia emissions were decreased in the probiotic-treated group. The fecal lactobacilli load and serum HDL-C levels were also improved by the probiotic intervention. The results suggested that JW15 supplementation could improve dogs’ health \[55\].

\( \text{Bacillus subtilis} \) (3.66 × 10^7 CFU/kg of the diet) and \( \text{Bacillus licheniformis} \) (3.66 × 10^7 CFU/kg of the diet) administration to healthy dogs (n = 8, 4 females, 4 males) for 20 days did not affect nutrient digestibility but improved fecal consistency and reduced the occurrence of fetid feces. The fecal biogenic amine content was decreased, thereby reducing the fecal odor in dogs of the probiotic group \[56\].

\( \text{L. acidophilus} \) D2/CSL (5 × 10^9 CFU/g of feed additive; pre-mixture contains 50 g of feed additive + 9950 g of maltodextrin; 20 g of pre-mixture per day) supplementation maintained a perfect body condition score for the whole duration of the study and improved the fecal moisture content in healthy dogs (n = 16) compared to that of the control group (n = 14). The study demonstrated that including \( \text{L. acidophilus} \) D2/CSL in a dog’s food could maintain weight and improve GI tract health in healthy dogs \[57\].

Supplementation of \( \text{Lactobacillus fermentum} \) AD1 (10^9 CFU) for 7 days showed that \( \text{L. fermentum} \) AD1 can survive in the canine GI tract, and increased fecal count of lactobacilli and enterococci and, also increased serum level of total lipid and total protein, and reduced the serum glucose level in healthy dogs \[58\]. Strompfová et al. \[59,60\] demonstrated that \( \text{L. fermentum} \) CCM 7421 (AD1 is denoted as CCM 7421; 10^7–10^8 CFU per dog per day) can survive in the canine GI tract and alter the microbiota (increased fecal count of LAB and reduced fecal count of clostridia, \text{Aeromonas sp.}, \text{E. coli} and \text{Pseudomonas sp.}) and metabolites (increased the total fecal concentration of SCFA such as butyric, formic, succinic, and valeric acid) \[59,60\] in healthy dogs.

### 3.2. Immune Immunomodulatory Properties

The serum levels of IL-6 and TNF-\( \alpha \) were increased in the \( \text{B. longum} \) KACC-91563-treated group compared to the control, indicating the immune–modulatory effects of the probiotics \[46\].

The serum levels of IgG, IFN-\( \alpha \), and fecal secretory IgA were increased and serum levels of TNF-\( \alpha \) was reduced in the probiotic (\( \text{L. casei} \) Zhang, \( \text{L. plantarum} \) P-8, and \( \text{B. animalis} \) subsp. \( \text{lactis} \) V9)-treated group \[48\].

IgA levels was not influenced upon administration of \( \text{L. kefiri} \) in healthy dogs \[50\].

The administration of 5 × 10^8 CFU/day of \( \text{E. faecium} \) SF68 to healthy young dogs at 8 weeks of age up to one year of age increased the fecal IgA level, canine-distemper-virus vaccine-specific IgG and IgA levels, and the proportion of the CD21^+ /major histocompatibility class II^+ compared to the placebo controls \[61\] (Table 2). Similarly, the administration of \( \text{Lactobacillus murinus} \) LbP2 (5 × 10^8 CFU/day) on alternating days for two weeks increased the total fecal IgA concentration in healthy dogs, indicating the immune immunomodulatory properties of LbP2 \[62\]. These findings will aid in using probiotics in canine nutrition for immune enhancement.
Table 2. The immune-modulatory effect of probiotic supplementation on the health status of dogs.

| Ref. | Model | Probiotic Used | Dose per Animal | Duration | Effect of Probiotic Supplementation |
|------|-------|----------------|-----------------|----------|------------------------------------|
| [46] | Healthy dogs (Probiotic group, n = 4; Placebo group, n = 4; Control group, n = 4) | Queso Blanco cheese containing *Bifidobacterium longum* KACC 91563 | $5 \times 10^6$ CFU/10 g cheese/day | 8 weeks | Increased the serum levels of IL-6 and TNF-α |
| [48] | Healthy dogs (Elderly probiotic group, n = 15; Elderly control group, n = 15; Young probiotic group, n = 12; Young control group, n = 12; Training probiotic group, n = 18; Training control group, n = 18) | *Lactobacillus casei* Zhang, *Lactobacillus plantarum* P-8, and *Bifidobacterium animalis* subsp. *lactis* V9 | Equal proportions of 3 probiotic strains in a final concentration of $2 \times 10^9$ CFU/g; Dosage: 10 g/day (Elderly group); 2 g/day (Young group); 4 g/day (Training group) | 60 days | Increased serum IgG, and IFNα levels, fecal SIgA levels in the probiotic-treated group |
| [61] | Healthy young dogs (Probiotic group, n = 7; Placebo group, n = 7) | *Enterococcus faecium* | $5 \times 10^9$ CFU/day | 1 year | Increased the fecal IgA, and canine distemper virus vaccine-specific circulating IgG and IgA. Increased the proportion of mature B cells. |
| [62] | Healthy dogs (Probiotic group, n = 7; Placebo group, n = 6) | *Lactobacillus murinus* LbP2 | $5 \times 10^9$ CFU/day; dosage on alternative days | 2 weeks | Increased the total fecal IgA concentration |
| [63] | Healthy dogs (Probiotic group, n = 5; Placebo group, n = 5) | *Lactobacillus johnsonii* CPN23 | $2-3 \times 10^8$ CFU/day | 9 weeks | Improved the phytohaemagglutinin-P reaction and the concentration of acetate and butyrate. Reduced fecal ammonia. No change in antibody reaction to sheep erythrocytes. |

IL-6: Interleukin-6; IFN-α: TNF-α: tumoral necrosis factor-alpha; IgG: Immunoglobulin G; Interferon-alpha; IgA: Immunoglobulin A; sIgA: secretory IgA.

*L. johnsonii* CPN23 (canine origin) administration to healthy adult Labrador dogs improved the fecal acetate and butyrate levels. *L. johnsonii* CPN23 also reduced fecal ammonia concentrations. Cell-mediated immune response was also evaluated as type-IV delayed-type hypersensitivity reaction to intradermally injected phytohaemagglutinin-P. CPN23 administration improved the cell-mediated immune response (as delayed-type hypersensitivity response in the form of increase in skin induration) in healthy dogs. There was no change in the antibody response to sheep erythrocytes. The study concluded that *L. johnsonii* CPN23 could be used to achieve improvements in canine health [63].

4. Health Benefits of Probiotic Supplementation in Diseased Dogs

4.1. Chronic Kidney Disease

VSL#3 supplementation effectively increased the glomerular filtration rate (GFR) in dogs with chronic kidney disease. In more detail, the 60-day administration of VSL#3 (a mixture of probiotics containing *L. casei*, *L. plantarum*, *L. acidophilus*, *Lactobacillus delbrueckii* subsp. *bulgaricus*, *B. longum*, *Bifidobacterium breve*, *Bifidobacterium infantis*, and *Streptococcus salivarius* subsp. *thermophilus*; 112 to 225 $\times 10^9$ CFU/10 kg body weight; every 24 h) to dogs (n = 30) with chronic kidney disease increased the GFR compared to that of the control group (n = 30) and baseline values [64].

4.2. Atopic Dermatitis

Marsella [19] reported that the prenatal and postnatal supplementation of *Lactobacillus rhamnosus* GG did not affect the clinical scores of atopic dermatitis (AD) in puppies. In detail, the mother dog was orally administered with *L. rhamnosus* GG ($20 \times 10^9$ CFU per capsule; 10 capsules per day) starting at the third week of gestation during the dog’s second pregnancy and continuing throughout lactation. Puppies (n = 9; 3 females, 6 males) of
the second litter (probiotic group) were administered *L. rhamnosus* GG (five capsules per day) starting at 3 weeks of age until 6 months of age. The puppies (at 3 weeks of age) of the first and second litters from same parents (two adult beagles with severe AD) were epicutaneously sensitized with *Dermatophagoides farinae*. The blood samples were then collected every 6 weeks (from 6 weeks of age until 6 months of age) to assess the serum-allergen-specific IgE. Severity of the clinical signs of AD were evaluated using Canine Atopic Dermatitis Extent and Severity Index (CADESI) scoring system before and after (initially after 6 h and then every 24 h for 5 days) allergen exposure. The puppies (n = 7; 5 females, 2 males) of the first litter (control group) developed clinical signs of AD and were strongly seropositive for IgE. The puppies of the second litter presented a lower serum titer against IgE and no significant change in AD clinical score. This study suggested that the supplementation of *L. rhamnosus* GG reduced the immunologic indicators of AD [19] (Table 3). As a follow-up [20] to the previous study [19], all the dogs (at the age of 2) in both litters (both the control and probiotic groups) were epicutaneously sensitized (biweekly application for 4 months) with ragweed, timothy, and *D. farinae* [20]. The clinical signs of the experimental dogs in both the control and probiotic groups were then evaluated. Allergen-specific IgE, TGF-β, and IL-10 levels were also measured. During the study, the dogs in the probiotic group were 3 years old, and the dogs in the control group were 4 years old. Normal dogs (n = 10 non-atopic Beagles; 4 females, 6 males; 4 years old) were used as the control group. IL-10 was higher in the control group, whereas IgE and TGF-β levels did not differ among the dogs of the control and probiotic groups. The CADESI scores of clinical signs were improved in the probiotic group. This study demonstrated that early administration of *L. rhamnosus* GG has long-term immunological and clinical effects in dogs [20].

Table 3. The effects of probiotic supplementation on the health status of dogs with atopic dermatitis.

| Ref. | Model | Probiotic Used | Dose per Animal | Duration | Effect of Probiotic Supplementation |
|------|-------|----------------|-----------------|----------|-----------------------------------|
| [19] | Dog puppies (Probiotic group, n = 9; Control group, n = 7) | *Lactobacillus rhamnosus* strain GG | 20 × 10⁹ CFU per capsule; 10 capsules per day (mother); 5 capsules per day (puppy) | Prenatal and postnatal (mother dog at third week of gestation and continuing throughout lactation); postnatal (Starting at the age of 3 weeks until 6 months old) | Reduced the immunologic indicators of AD. No significant reduction in clinical signs of AD. |
| [65] | Dogs with AD (Probiotic group, n = 32; Placebo group, n = 10) | *Lactobacillus sakei* probio-65 | 2 × 10⁹ CFU/day | 2 months | Reduced the CADESI score |
| [66] | Dogs with AD (Probiotic group, n = 7; Placebo group, n = 4) | *Bifidobacterium longum* | 5 × 10¹⁰ CFU/day | 12 weeks | Reduced the CADESI score |

AD: Atopic dermatitis; CADESI: Canine atopic dermatitis extent and severity index.

The oral administration of probiotic strain *Lactobacillus sakei* probio-65 (2 × 10⁹ CFU per gram per day for two months) to dogs (n = 32) diagnosed with canine AD effectively reduced the disease severity index measured by CADESI scoring system. The double-blind placebo-controlled study demonstrated that *L. sakei* probio-65 could be considered an adjuvant therapeutic agent to manage canine AD [65].

*B. longum* (5 × 10¹⁰ CFU/day) was orally supplemented in dogs with AD for 12 weeks, and the severity of the skin lesions was assessed using the CADESI score. Pruritus severity was also assessed using the pruritus visual analog scale (PVAS). The transepidermal water loss (TEWL) and the medication score was also recorded. The data were collected every four weeks of the study. The results revealed that the administration of *B. longum* progressively reduced the CADESI score compared to the baseline, whereas probiotic supplementation was not effective in reducing the TEWL, PVAS, and medication scores. The study determined that *B. longum* could improve skin lesions in dogs [66].
4.3. Gastrointestinal Diseases and Abnormalities

4.3.1. Chronic Enteropathy

The dogs with chronic enteropathies were administered *Saccharomyces boulardii* (1 × 10⁹ CFU/kg/12 h) for 60 days in addition to the standard treatment. The Canine Chronic Enteropathy Clinical Activity Index (CCECAI), stool consistency and frequency, and body condition score were improved after the probiotic treatment. This study suggested that *S. boulardii* could be used as a probiotic for canines to treat enteropathies [67] (Table 4).

Table 4. The effects of probiotic supplementation on the health status of dogs with gastrointestinal diseases and abnormalities.

| Ref. | Model | Probiotic/Prebiotic Used | Dose per Animal | Duration | Effect of Probiotic Supplementation |
|------|-------|--------------------------|-----------------|----------|------------------------------------|
| [21] | Dogs with FRD (Probiotic group, n = 11; Placebo group, n = 10) | *Lactobacillus acidophilus* NCC2628, *L. acidophilus* NCC2766, *Lactobacillus johnsonii* NCC2767 | 10⁹ CFU of each probiotic strain/day | 4 weeks | Reduced Enterobacteriaceae count, improved *Lactobacillus* spp. count, improved clinical signs. |
| [22] | Dogs with diarrhea (Probiotic group, n = 25; Placebo group, n = 19) | *Lactobacillus fermentum* VET 9A, *Lactobacillus rhamnosus* VET 16A, and *Lactobacillus plantarum* VET 14A | Daily dose: 2 × 10⁸ CFU/mL of 3 bacterial strains | 7 days | Improved stool consistency, normalized the appetite, decreased *Clostridium perfringens* and *Enterococcus faecium* count. |
| [23] | Dogs with acute diarrhea (Probiotic group, n = 61) | *E. faecium* 4b1707 | 2 × 10⁶ CFU/gram paste; dosage according to body weight; 3 times per day (every 8 h) | 10 days | Reduced the duration of diarrhea and improved acute diarrhea. |
| [24] | Dogs with ACD (Probiotic group, n = 19; Placebo group, n = 19; Metronidazole group, n = 10) | *Bifidobacterium bifidum* VPBB-6, *Bifidobacterium longum* VPBL-5, *Bifidobacterium animalis* VPBA-4, *Bifidobacterium infantis* VPBI-6, *L. acidophilus* VPLA-4, *L. plantarum* VPLP-5, *Lactobacillus casei* VPLC-1, *Lactobacillus brevis* VPLB-5, *Lactobacillus reuteri* VPLR-1, and *Lactobacillus bulgaricus* VPLB-7 | 30 × 10⁸ CFU/425 mg/capsule; 125 mg/4–10 kg body weight; 250 mg/10.1–20 kg body weight; 400 mg/20.1–45 kg body weight; dose twice a day | 10 days | Improved stool consistency. |
| [25] | Dogs with diarrhea (Probiotic group, n = 16; Placebo group, n = 16) | Metronidazole and *E. faecium* SF68 | 5 × 10⁶ CFU/day | 7 days | Eliminated *Giardia* cysts and cured diarrhea. |
| [67] | Dogs with chronic enteropathies (Probiotic group, n = 6; Placebo group, n = 7) | *Saccharomyces boulardii* | 1 × 10⁹ CFU/kg/12 h | 60 days | CCECAI, fecal consistency and frequency, and body condition score were improved. |
| [68] | Dogs with chronic enteropathy (n = 12; Disease dogs during 1st visit (Control) and 2nd visit (Treatement) after 6 weeks of treatment) | *E. faecium* and FOS | 1 × 10⁶ CFU/day | 6 weeks | No change in the expression of the inflammasome or its components. |
| [69] | Dogs with IDB (Probiotic group, n = 10; Control group, n = 10) | VSL#3 (*L. casei*, *L. plantarum*, *L. acidophilus*, and *Lactobacillus delbrueckii* subsp. *bulgaricus*, *L. longum*, *Bifidobacterium breve*, *B. infantis*, and *Streptococcus salivarius* subsp. *thermophilus*) | 112–225 × 10⁶ CFU/10 kg/day | 60 days | Decreased the clinical and histological scores. Normalized dysbiosis. Enhanced regulatory T-cell markers. |
| [70] | Dogs with diarrhea (Probiotic group, n = 20; Placebo group, n = 20) | *L. casei* Zhang, *L. plantarum* P-8, and *Bifidobacterium animalis* subsp. *lactis* V9 | Probiotic mixture (equal proportion of 3 probiotic strain) containing 3 × 10⁹ CFU/g (each *Lactobacillus* strain), 4 × 10⁹ CFU/g (*Bifidobacterium* strain); Dosage: 10 g/day (elderly dogs); 4 g/day (young dogs); 2 g/day (adult dogs) | 60 days | Increased the abundance of *L. johnsonii*, *L. reuteri*, *L. acidophilus*, *Butyricicoccus pullicicorum* Reduced the count of *C. perfringens* and *Stenotrophomonas maltophilia* |
| [71] | Dogs with DAD (Probiotic group, n = 13; Placebo group, n = 7) | *Lactobacillus murinus* LbP2 | 5 × 10⁶ CFU/day | 5 days | Improved the clinical score. |

FRD: Food responsive diarrhea; DAD: Distemper-associated diarrhea; AHDS: Acute hemorrhagic diarrhea syndrome; ACD: Acute canine diarrhea; IDB: Inflammatory bowel disease; FOS: Fructo-oligosaccharides; CCECAI: Canine Chronic Enteropathy Clinical Activity Index. *30 × 10⁶ CFU/capsule as per the label of the probiotic product, 70 × 10⁹ CFU/capsule as per the assessment at the initiation of the study [23].

The supplementation of *E. faecium* (1 × 10⁹ CFU/day) and FOS for six weeks did not change the expression of the inflammasome and its associated components in dogs with...
chronic enteropathy. The study observed that the inflammasome and its components could be partially involved in chronic enteropathy’s inflammatory process [68].

VSL#3 containing L. casei, L. plantarum, L. acidophilus, L. delbrueckii subsp. bulgaricus, B. longum, B. breve, B. infantis, and S. salivarius subsp. thermophilus (112 to 225 × 10⁹ CFU/10 kg/day) was administered to dogs suffering from idiopathic inflammatory bowel disease (IBD, which is a chronic enteropathy) for 60 days. The probiotic supplementation improved the clinical and histological scores and reduced CD3+ T-cell infiltration. The probiotic treatment enhanced regulatory T-cell markers, such as FoxP3+ and TGF-β+. IBD-associated dysbiosis was normalized in the probiotic treatment group. Clinical and histological improvements were not observed in the control (prednisone- and metronidazole-treated) group. This study noted that future, more extended, studies are needed to confirm the efficiency of VSL#3 [69].

The supplementation of a probiotic mixture (L. acidophilus NCC2628, L. acidophilus NCC2766, and L. johnsonii NCC2767; 10¹⁰ CFU of each probiotic strain/day) effectively reduced the expression of IL-10 and increased the expression of IFN-γ in dogs suffering from food responsive diarrhea (which is a chronic enteropathy) treated with an elimination diet; this mixture also reduced and increased the abundance of Enterobacteriaceae and Lactobacillus, respectively. Overall, the clinical signs of diarrhea were improved after the intervention of the probiotic mixture [21].

4.3.2. Acute Diarrhea

Daily intervention of fermented sour milk products containing 2 × 10⁹ CFU/mL of L. fermentum VET 9A, L. rhamnosus VET 16A, and L. plantarum VET 14A for seven days normalized the stool consistency, and improved appetite in the dogs with acute diarrhea. The abundance of pathogenic strains such as C. perfringens and E. faecium were also decreased during the probiotic treatment [22]. E. faecium 4b1707 (2 × 10⁹ CFU/gram paste; dosage according to body weight; three times per day (every 8 h)) intervention for 10 days reduced the duration of diarrhea and improved acute diarrhea in dogs [23].

Intervention of probiotic mixture containing B. bifidum VPBB-6, B. longum VPBL-5, B. animalis VPBA-4, B. infantis VPBI-6, L. acidophilus VPLA-4, L. plantarum VPLP-5, L. casei VPLC-1, Lactobacillus brevis VPLB-5, Lactobacillus reuteri VPLR-1, and Lactobacillus bulgaricus VPLB-7 (30 × 10⁹ CFU/425 mg/capsule as per the label of the probiotic product, 70 × 10⁹ CFU/capsule as per the assessment at the initiation of the study; 125 mg/4–10 kg body weight; 250 mg/10.1–20 kg body weight; 400 mg/20.1–45 kg body weight; dose twice a day) for 10 days improved the stool consistency in dogs with acute canine diarrhea [24].

4.3.3. Nonspecific Diarrhea

In addition to metronidazole, E. faecium SF68 (5 × 10⁸ CFU/day) was administered for seven days to dogs with diarrhea. Normalization of the stool and the elimination of Giardia spp. cysts were observed in dogs treated with dual therapy compared to the group treated with the drug alone. Completely cured diarrhea was observed among dogs in the dual-therapy group [25]. But due to the small number of positive samples in the group supplemented with E. faecium SF68, they have not statistically compared the prevalence of Giardia and clinical response rates between groups, which is the limitation of this study [25], so further studies with larger sample sizes and statistical comparison between groups are required to conclude the efficacy of SF68 on Giardia control.

The intervention of a probiotic cocktail containing equal proportion of L. casei Zhang, L. plantarum P-8, and B. animalis subsp. lactis V9 (probiotic mixture containing 3 × 10⁹ CFU/g (each Lactobacillus strain), 4 × 10⁸ CFU/g (Bifidobacterium strain); Dosage: 10 g/day for elderly dogs; 4 g/day for young dogs; 2 g/day for adult dogs) for 60 days effectively altered the gut microbiome of dogs with diarrhea. The abundance of L. johnsonii, L. reuteri, L. acidophilus, and Butyricicoccus pullicicorum increased, and the count of C. perfringens and Stenotrophomonas maltophilia decreased. Moreover, the pathways involved in the metabolism of amino acids and the biosynthesis of secondary metabolites were activated,
and the virulence-associated pathways were downregulated. This study suggested that a probiotic intervention could improve dog health through positive regulation of the gut microbiome [70].

4.3.4. Other Diseases Associated with Diarrhea or Prevention of Gastrointestinal Infections

The effect of the oral supplementation of *Lactobacillus murinus* LbP2 to dogs suffering from canine distemper virus-associated diarrhea was also studied. In detail, an intervention of LbP2 ($5 \times 10^9$ CFU/day) administered to dogs for five days improved the clinical score of the disease, stool consistency, stool output, appetite, and mental health. The results suggested that LbP2 could be used to manage canine distemper virus-associated diarrhea [71].

German Shepherd ($n = 36$, 18 females, 18 males) and Yorkshire puppies ($n = 36$, 18 females, 18 males) were vaccinated for distemper and parvovirus at 6 weeks of age, and were vaccinated for distemper, hepatitis, leptospirosis, parainfluenza, parvovirus at 8 weeks and 12 weeks of age. These puppies were randomly grouped to fed with diet supplemented with either of the probiotic, *L. rhamnosus* MP01 ($\sim 9 \log_{10}$ CFU/day) or *L. plantarum* MP02 ($\sim 9 \log_{10}$ CFU/day) (two probiotic groups) or diet without probiotics (control group) for 8 weeks (started at 5 weeks of age). Each group (two probiotic groups and one control group) had German Shepherd ($n = 12$, 6 females, 6 males) and Yorkshire puppies ($n = 12$, 6 females, 6 males). GI infection (symptoms such as diarrhea in the presence or absence of fever or vomiting) during the duration (2 months) of the study. *L. rhamnosus* MP01 and *L. plantarum* MP02 interventions effectively prevented gastrointestinal infections in German Shepherd and Yorkshire puppies compared to that of the control group, and also increased the SCFAs concentration in the feces of dogs of probiotic group [72].

Since only single study are available for distemper virus-associated diarrhea [71], and for the prevention of gastrointestinal infections in puppies [72], more studies are needed to suggest the health promoting probiotic effect in those cases.

5. Discussion

Microbiota shape the health status of pets. Subsequently, dog owners play a role in determining the microbiota of dogs through their food. Pet foods are formulated to contain the carbohydrates, proteins, fats, minerals, and vitamins, etc. Presently, some pet foods include probiotics in their formulations. Several probiotic supplements have been reported to have health-promoting properties for both healthy and diseased dogs. Probiotics isolated from fresh fecal swabs of healthy dogs could also be used as a potent probiotic candidate as a dietary supplement for dogs [73,74].

Positive regulation of the microbial ecology in the GI tract has systemic effects. Studies have confirmed that the intervention of probiotics could change the microbiota of dogs. The supplementation of probiotic preparations was shown to increase the abundance of beneficial microbes, such as *Lactobacillus* spp. and *Bifidobacterium* spp., and suppress the growth of harmful microbes, such as *Enterobacteriaceae* and *C. perfringens* [70].

The additional functional foods that are nutritive or nonnutritive and required dietary components to promote the host health are referred as functional nutrition. Functional nutrients and functional foods with immune-regulatory properties are termed as immunonutrition. Vitamins (D and E), minerals (Zinc), omega-3 polyunsaturated fatty acids, phytochemicals such as epigallocatechin-3-gallate, microbial metabolites such as SCFA, and probiotics have immunomodulating potentials. The vitamins, zinc, and SCFA are involved in intestinal homeostasis and maintain intestinal integrity [75–77]. Supplementation of vitamin E and selenium enhanced the immune response in vaccinated dogs, and especially increased the IgG concentration compared to the control, and offered the highest protection [78]. The supplementation of eicosapentaenoic acid (EPA) and docosahexaenoic acid showed significant health improvement in diseased dogs [79]. The intestinal dysbiosis affects the availability of beneficial microbial metabolites, such as SCFA. The use of antibiotics might deplete the anaerobic bacterial load, and drain the SCFA content, particularly
butyrate concentrations. Besides, over-immunomodulation has to be taken into account so that the naïve functions, such as eliminating microbial infections, of the immune system can work accordingly. Probiotic supplementation resumes the healthy intestinal microbiota and promotes the ideal immune regulation. Thus, factors such as selection of the probiotic strain, dose, and duration have to be optimized properly before practical applications [77].

Dogs cannot synthesize vitamins, but vitamins can be obtained from their diet and the gut microbiota. The gut microbiota has been considered as a rich source of vitamins [80]. The deficiency of folate and cobalamin is considerably related to and maintains gastrointestinal homeostasis. The deficiency of folate might lead to the reduction of regulatory T (Treg) cells (subpopulation of T cells involved in the immune homeostasis), which cause impaired gut homeostasis, and are prone to intestinal inflammation [81]. Cobalamin is a marker of gastrointestinal diseases in companion animals due to the availability and detectability of cobalamin in serum, even in the serum of animals fed with a low cobalamin diet. Hypothetically, reduced serum cobalamin is due to the utilization of available cobalamin by the increased number of intestinal bacteria [82]. The dogs with diarrhea were reported for the low serum cobalamin concentration [83]. Allenspach et al. [84] reported that a decrease in serum cobalamin concentration was observed in dogs with chronic enteropathies [84], and the oral supplementation of cobalamin rectified the deficiency [85]. Sauter et al. [21] reported that the probiotic mixture intervention did not significantly affect the cobalamin concentration, while the serum folate concentration was increased [21]. Hypocobalaminemia is associated with negative outcomes in dogs with chronic gastrointestinal disease [86]. The probiotics were used to treat GI disorders [58], and their potential effect hinges on the bacterial strain [3]. Though probiotic bacteria have been reported to produce vitamins [80,87], the administration of *E. faecium* SF68 resulted in moderate hypocobalaminemia in healthy dogs [53]. Thus, the intake of *E. faecium* SF68 longer than 14 days might lead to an intense decrease in the levels of cobalamin in healthy dogs, which should be noted, and further studies are required to know whether SF68 is safe or not. The selection of probiotics, principally to treat diseased dogs, is more considerable and prompt the need for caution as the mechanism of action of probiotics might be affected by many factors and some clinical aspects are not perfectly known, especially in diseased dogs.

The production of SCFA in dogs is not fully dependent on the dietary carbohydrate content [88]. The altered SCFA level affects gastrointestinal health. SCFAs, particularly butyrate, might be used as a preferred energy source for the colonocytes [89]. It has been reported that the SCFA has a regulatory effect on gastrointestinal motility [90]. The gastrointestinal disease developments may be related to the changes in intestinal microbial composition and its function, especially the reduced production of SCFA and other metabolites [91]. For example, dogs with acute and chronic diarrhea who had dysbiosis were found to have reduced SCFA-producing bacteria [92,93], and significant reduction of propionate concentration has been reported in dogs with acute diarrhea [94]. Probiotic supplementation amended the microbial population in dogs and augmented the production of SCFA. *B. longum* KACC 91563 [45] and *L. fermentum* CCM 7421 [59] intervention, which significantly reduced the harmful bacterial count and increased the SCFA levels in healthy companion dogs [45,59]. Nevertheless, not all the probiotic interventions increased the SCFA level in experimental dogs. Gagné et al. [95] reported that the intervention of synbiotic preparation (5 g of synbiotic per dog per day) containing *E. faecium* SF68 (56.7 mg/g; 5.67 × 10⁸ CFU/g), *Bacillus coagulans* (2.5 mg/g; 3.75 × 10⁷ CFU/g), *L. acidophilus* (14.4 mg/g; 7.2 × 10⁸ CFU/g), fructooligosaccharides (400 mg/g), mannooligosaccharides (80 mg/g), Vitamin B1 (2.5 mg/g), Vitamin B2 (0.8 mg/g), Vitamin B3 (19.2 mg/g), Vitamin B6 (0.8 mg/g) for 6 weeks showed no significant changes in acetate, propionate, and butyrate concentrations in healthy training sled dogs of synbiotic group (n = 9) compared to that of the placebo group (n = 8) [95].

A recent systemic review of 12 studies that reported the clinical effect of probiotics in dogs with GI disease stated that probiotic supplementation showed a very limited and unimportant effect on the treatment or prevention of acute GI disease in dogs, and
non-significant improvement in chronic GI disease [96]. A very recent review stated that probiotics are beneficial in some acute or infectious GI conditions in dogs and are slightly beneficial in food-responsive or antibiotic-responsive chronic enteropathies in dogs [97].

The evidence suggests that nutrition influences the composition of the microbiota and is thus strongly associated with gastrointestinal health [98]. The development of probiotic-based foods for dogs is required to promote the health benefits for both healthy and diseased companion pets. However, further research is needed to develop effective probiotic preparations to improve the well-being of domestic dogs.

6. Conclusions

The literature survey provided in this paper revealed that probiotics might promote the health and well-being of healthy dogs, that they could be considered as an adjuvant therapeutic agent to manage AD [19,20,65], and could help dogs by improving their clinical symptoms of diarrhea [21–25]. The possible mechanisms of action of probiotics include persistent colonization in the host and restoring the normal microbiota by modulating the commensal microbiota, thereby improving the availability of beneficial microbial metabolites, such as SCFA, and reducing the pathogenic microbial load in the host system, and/or improving the host immune response by exhibiting an immunomodulatory effect on maintaining or improving the health status of dogs (Figure 1).

![Figure 1. Possible mechanism of probiotic action on improving the health status of dogs.](image)

However, a few studies [41,44,50] showed no positive effects on the health status of dogs upon intervention of *E. faecium* NCIB 10415 (isolated from healthy dog feces) [41], *Lactobacillus, Bifidobacterium*, and *Bacillus* species [44], and *Lactobacillus kefiri* [50]. Thus, more studies are required to discover the negative effects and positive effects of probiotics in healthy and diseased dogs for the evidence-based use of probiotics in dogs. The influence of sources of probiotic bacteria could be concluded by comparing the health beneficial effects of same probiotic LAB species/strains derived from different origins. Thus, an abundance of studies based on the same probiotic species/strains of different origin is required to compare the health beneficial effect between them and conclude the influence of origin on the health status of dogs. The protective effects of probiotic supplements depend on the strain, dose, duration of the intervention, and combinations with other strains. Therefore, more controlled trials are required to find effective and safe probiotics by characterizing the safe probiotic preparations in terms of the optimum dose, either for specific dog breeds or for all dog breeds, to discover their efficacy when used as a single species/strain or multi-species/strain, and for the treatment of different diseases in compliance with ethical standards. In conclusion, further, much larger studies are needed to explore the beneficial implications of probiotics at a broader level, paving the way for the development and/or improving the pharmacological activity of nutraceuticals, which include probiotics for dogs.

**Author Contributions:** Conceptualization, P.K., B.S.S. and C.C.; writing—original draft preparation, B.S.S. and P.K.; writing—review and editing, P.K., B.S.S. and C.C.; supervision, B.S.S. and C.C.; project administration, C.C.; funding acquisition, C.C. All authors have read and agreed to the published version of the manuscript.
Funding: This project was partially supported by Chiang Mai University, Chiang Mai, Thailand.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: The authors gratefully acknowledge the Faculty of Pharmacy, and Chiang Mai University, Chiang Mai, Thailand.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. National Research Council. Nutrient Requirements of Dogs and Cats; The National Academies Press: Washington, DC, USA, 2006. [CrossRef]
2. Thatcher, C.D.; Hand, M.S.; Remillard, R.L. Small animal clinical nutrition: An interactive process. In Small Animal Clinical Nutrition, 5th ed.; Hand, M.S., Thatcher, C.D., Remillard, R.L., Roudybush, P., Novotny, B.J., Eds.; Mark Morris Institute: Topeka, Kansas, 2010; pp. 1–18.
3. Grzesikowiak, L.; Endo, A.; Beasley, S.; Salminen, S. Microbiota and probiotics in canine and feline welfare. Anaerobe 2015, 34, 14–23. [CrossRef] [PubMed]
4. Pilla, R.; Suchodolski, J.S. The Gut Microbiome of Dogs and Cats, and the Influence of Diet. Vet. Clin. Small Anim. 2021, 51, 605–621. [CrossRef] [PubMed]
5. Abenavoli, L.; Scarpellini, E.; Colica, C.; Bocciuto, L.; Salehi, B.; Sharifi-Rad, J.; Aiello, V.; Romano, B.; De Lorenzo, A.; Izzo, A.A.; et al. Gut Microbiota and Obesity: A Role for Probiotics. Nutrients 2019, 11, 2690. [CrossRef] [PubMed]
6. Abdellatif, B.; McVeigh, C.; Bendriss, G.; Chaari, A. The Promising Role of Probiotics in Managing the Altered Gut in Autism Spectrum Disorders. Int. J. Mol. Sci. 2020, 21, 4159. [CrossRef]
7. Arora, K.; Green, M.; Prakash, S. The microbiome and Alzheimer’s Disease: Potential and limitations of prebiotic, symbiotic, and probiotic formulations. Front. Bioeng. Biotechnol. 2020, 8, 537847. [CrossRef]
8. FAO/WHO. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria; Food and Agriculture Organization of the United Nations: Cordoba, Argentina, 2001.
9. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 506–514. [CrossRef]
10. Collins, J.; Thornton, G.; Sullivan, G. Selection of probiotic strains for human applications. Int. Dairy J. 1998, 8, 487–490. [CrossRef]
11. Bajagai, Y.S.; Klieve, A.V.; Dart, P.J.; Bryden, W.L. Probiotic (Bifidobacterium animalis strain AHC7) fed to growing dogs. J. Anim. Physiol. Anim. Nutr. 2012, 96, 735–740. [CrossRef]
12. Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. A review of the role of probiotic supplementation in dental caries. Probiotics Antimicrob. Proteins 2020, 12, 1300–1309. [CrossRef]
13. Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. The role of probiotics in colorectal cancer management. Evid. Based Complement. Alternat. Med. 2020, 2020, 3535982. [CrossRef]
14. Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. A mini-review of human studies on cholesterol-lowering properties of probiotics. Sci. Pharm. 2019, 87, 26. [CrossRef]
15. Kesika, P.; Sivamaruthi, B.S.; Chaiyasut, C. Do probiotics improve the health status of individuals with diabetes mellitus? A review on outcomes of clinical trials. Bio. Med. Res. Int. 2019, 2019, 1531567. [CrossRef] [PubMed]
16. Ashraf, R.; Shah, N.P. Immune system stimulation by probiotic microorganisms. Crit. Rev. Food Sci. Nutr. 2014, 54, 938–956. [CrossRef]
17. Kelley, R.L.; Park, J.S.; O’Mahony, L.; Minikhiem, D.; Fix, A. Safety and tolerance of dietary supplementation with a canine-derived probiotic (Bifidobacterium animalis strain AHCF) fed to growing dogs. Vet. Ther. 2010, 11, E1–E14. [PubMed]
18. Marrella, R. Evaluation of Lactobacillus rhamnosus strain GG for the prevention of atopic dermatitis in dogs. Am. J. Vet. Res. 2009, 70, 735–740. [CrossRef]
19. Marrella, R.; Santoro, D.; Ahrens, K. Early exposure to probiotics in a canine model of atopic dermatitis has long-term clinical and immunological effects. Vet. Immunol. Immunopathol. 2012, 146, 185–189. [CrossRef]
20. Sauter, S.N.; Benyacoub, J.; Allerspach, K.; Gaschen, F.; Ontsouka, E.; Reuteler, G.; Cavadini, C.; Knorr, R.; Blum, J.W. Effects of probiotic bacteria in dogs with food responsive diarrhea treated with an elimination diet. J. Anim. Physiol. Anim. Nutr. 2006, 90, 269–277. [CrossRef]
21. Gómez-Gallego, C.; Junnila, J.; Männikkö, S.; Hämeenoja, P.; Valtonen, E.; Salminen, S.; Beasley, S. A canine-specific probiotic product in treating acute or intermittent diarrhea in dogs: A double-blind placebo-controlled efficacy study. Vet. Microbiol. 2016, 197, 122–128. [CrossRef]
23. Nixon, S.L.; Rose, L.; Muller, A.T. Efficacy of an orally administered anti-diarrheal probiotic paste (Pro-Kolin Advanced) in dogs with acute diarrhea: A randomized, placebo-controlled, double-blinded clinical study. J. Vet. Intern. Med. 2019, 33, 1286–1294. [CrossRef]
24. Shimbalger, J.; Montalbano, C.; Morelli, G.; Buckley, G.J. A randomized double blinded placebo-controlled clinical trial of a probiotic or metronidazole for acute canine diarrhea. Front. Vet. Sci. 2019, 6, 163. [CrossRef]
25. Ferinmore, A.; Martin, L.; Lappin, M.R. Evaluation of Metronidazole with and without *Enterococcus faecium* SF68 in shelter dogs with diarrhea. Top. Companion Anim. Med. 2017, 32, 100–103. [CrossRef]
26. Coelho, L.P.; Kultima, J.R.; Costea, P.I.; Fournier, C.; Pan, Y.; Czarnecki-Maulden, G.; Hayward, M.R.; Forslund, S.K.; Schmidt, T.S.B.; Descombes, P.; et al. Similarity of the dog and human gut microbiomes in gene content and response to diet. Microbiome 2018, 6, 72. [CrossRef]
27. Hooda, S.; Minamoto, Y.; Suchodolski, J.S.; Swanson, K.S. Current state of knowledge: The canine gastrointestinal microbiome. Anim. Health Res. Rev. 2012, 13, 78–88. [CrossRef]
28. Redfern, A.; Suchodolski, J.; Jergens, A. Role of the gastrointestinal microbiota in small animal health and disease. Vet. Rec. 2017, 181, 370. [CrossRef] [PubMed]
29. Brown, C.M.; Staley, C.; Wang, P.; Dalzell, B.; Chun, C.L.; Sadowsky, M.J. A High-Throughput DNA-Sequencing Approach for Determining Sources of Fecal Bacteria in a Lake Superior Estuary. Environ. Sci. Technol. 2017, 51, 8263–8271. [CrossRef] [PubMed]
30. German, A.J.; Day, M.J.; Ruaux, C.G.; Steiner, J.M.; Williams, D.A.; Hall, E.J. Comparison of direct and indirect tests for small intestinal bacterial overgrowth and antibiotic-responsive diarrhea in dogs. J. Vet. Intern. Med. 2003, 17, 33–43. [CrossRef] [PubMed]
31. Mentula, S.; Harmoinen, J.; Heikkilä, M.; Westermarck, E.; Rautio, M.; Huovinen, P.; Könönen, E. Comparison between cultured small-intestinal and fecal microbiotas in beagle dogs. Appl. Environ. Microbiol. 2005, 71, 4169–4175. [CrossRef]
32. Suchodolski, J.S. Intestinal microbiota of dogs and cats: A bigger world than we thought. Am. J. Vet. Res. 2011, 41, 261–272. [CrossRef] [PubMed]
33. Garcia-Mazcorro, J.F.; Dowd, S.E.; Poulsen, J.; Steiner, J.M.; Suchodolski, J.S. Abundance and short-term temporal variability of fecal microbiota in healthy dogs. Microbiologysopen 2012, 1, 340–347. [CrossRef]
34. Jha, A.R.; Shimbalger, J.; Tanprasertsuk, J.; Perry, L.; Massey, D.; Honaker, R.W. Characterization of gut microbiomes of household pets in the United States using a direct-to-consumer approach. PLoS ONE 2020, 15, e0227289. [CrossRef]
35. Pilla, R.; Suchodolski, J.S. The Role of the Canine Gut Microbiome and Metabolome in Health and Gastrointestinal Disease. Front. Vet. Sci. 2020, 6, 498. [CrossRef]
36. Suchodolski, J.S.; Ruaux, C.G.; Steiner, J.M.; Fetz, K.; Williams, D.A. Assessment of the qualitative variation in bacterial microflora among compartments of the intestinal tract of dogs by use of a molecular fingerprinting technique. Am. J. Vet. Res. 2005, 66, 1556–1562. [CrossRef]
37. Honneffer, J.B.; Steiner, J.M.; Lidbury, J.A.; Suchodolski, J.S. Variation of the microbiota and metabolome along the canine gastrointestinal tract. Metabolomics 2017, 13, 26. [CrossRef]
38. Suchodolski, J.S.; Camacho, J.; Steiner, J.M. Analysis of bacterial diversity in the canine duodenum, jejunum, ileum, and colon by comparative 16S rRNA gene analysis. FEMS Microbiol. Ecol. 2008, 66, 567–578. [CrossRef] [PubMed]
39. Handl, S.; Dowd, S.E.; Garcia-Mazcorro, J.F.; Steiner, J.M.; Suchodolski, J.S. Massive parallel 16S rRNA gene pyrosequencing reveals highly diverse fecal bacterial and fungal communities in healthy dogs and cats. FEMS Microbiol. Ecol. 2011, 76, 301–310. [CrossRef]
40. Hand, D.; Wallis, C.; Colyer, A.; Penn, C.W. Pyrosequencing the canine faecal microbiota: Breadth and depth of biodiversity. PLoS ONE 2013, 8, e53115. [CrossRef] [PubMed]
41. Vahjen, W.; Männner, K. The effect of a probiotic *Enterococcus faecium* product in diets of healthy dogs on bacteriological counts of *Salmonella* spp., *Campylobacter* spp. and *Clostridium* spp. in feces. Arch. Anim. Nutr. 2003, 57, 229–233. [CrossRef] [PubMed]
42. Biagi, G.; Cipollini, I.; Pompei, A.; Zaghini, G.; Matteuzzi, D. Effect of a *Lactobacillus animalis* strain on composition and metabolism of the intestinal microflora in adult dogs. Vet. Microbiol. 2007, 124, 160–165. [CrossRef]
43. González-Ortiz, G.; Castillejos, L.; Mallo, J.J.; Ángels Calvo-Torras, M.; Dolores Baucells, M. Effects of dietary supplementation of *Bacillus amyloliquefaciens* CECT 5940 and *Enterococcus faecium* CECT 4515 in adult healthy dogs. Arch. Anim. Nutr. 2013, 67, 406–415. [CrossRef]
44. Hutchins, R.G.; Bailey, C.S.; Jacob, M.E.; Harris, T.L.; Wood, M.W.; Saker, K.E.; Vaden, S.L. The effect of an oral probiotic containing Lactobacillus, Bifidobacterium, and Bacillus species on the vaginal microbiota of spayed female dogs. J. Vet. Intern. Med. 2013, 27, 1368–1371. [CrossRef]
45. Park, H.E.; Kim, Y.J.; Do, K.H.; Kim, J.K.; Ham, J.S.; Lee, W.K. Effects of Queso Blanco cheese containing *Bifidobacterium longum* KACC 91563 on the intestinal microbiota and short chain fatty acid in healthy companion dogs. Korean J. Food Sci. Anim. Resour. 2018, 38, 1261–1272. [CrossRef] [PubMed]
46. Park, H.E.; Kim, Y.J.; Kim, M.; Kim, H.; Do, K.H.; Kim, J.K.; Ham, J.S.; Lee, W.K. Effects of Queso Blanco cheese containing *Bifidobacterium longum* KACC 91563 on fecal microbiota, metabolite and serum cytokine in healthy beagle dogs. Anaerobe 2020, 64, 102234. [CrossRef] [PubMed]
47. Vazquez-Mendoza, P.; Elghandour, M.M.M.; Alaba, P.A.; Sánchez-Aparicio, P.; Alonso-Fresán, M.U.; Barbabosa-Pliego, A.; Salem, A.Z. M. Antimicrobial and bactericidal impacts of *Bacillus amyloliquefaciens* CECT 5940 on fecal shedding of pathogenic bacteria in dairy calves and adult dogs. *Microb. Pathog.* 2018, 114, 458–463. [CrossRef]

48. Xu, H.; Huang, W.; Hou, Q.; Kwok, L.Y.; Laga, W.; Wang, Y.; Ma, H.; Sun, Z.; Zhang, H. Oral administration of compound probiotics improved canine feed intake, weight gain, immunity and intestinal microbiota. *Front. Immunol.* 2019, 10, 666. [CrossRef]

49. Kim, D.H.; Jeong, D.; Kang, I.B.; Lim, H.W.; Cho, Y.; Seo, K.H. Modulation of the intestinal microbiota of dogs by kefir as a functional dairy product. *J. Dairy Sci.* 2019, 102, 3903–3911. [CrossRef]

50. Gasparo, A.; Zannoni, A.; Turrioni, S.; Barone, M.; Sabetti, M.C.; Zannoni, R.G.; Forni, M.; Brigidi, P.; Pietra, M. Influence of *Lactobacillus kefiri* on intestinal microbiota and fecal IgA content of healthy dogs. *Front. Vet. Sci.* 2020, 7, 146. [CrossRef]

51. Marcinňková, M.; Simonová, M.; Strompfová, V.; Lauková, A. Oral application of *Enterococcus faecium* strain EE3 in healthy dogs. *Folia Microbiol.* 2006, 51, 239–242. [CrossRef]

52. Kumar, S.; Pattanaik, A.K.; Sharma, S.; Jadhav, S.E. Species-specific probiotic *Lactobacillus johnsonii* CPN23 supplementation modulates blood biochemical profile and erythrocytic antioxidant indices in Labrador dogs. *Indian J. Anim. Sci.* 2016, 86, 918–924.

53. Lucena, R.; Olmedilla, A.B.; Blanco, B.; Novales, M.; Ginel, P. Effect of *Enterococcus faecium* SF68 on serum cobalamin and folate concentrations in healthy dogs. *J. Small Anim. Pract.* 2018, 59, 438–443. [CrossRef] [PubMed]

54. Lucena, R.; Novales, M.; Blanco, B.; Hernández, E.; Ginel, P. Effect of probiotic *Enterococcus faecium* SF68 on liver function in healthy dogs. *J. Vet. Intern. Med.* 2019, 33, 2628–2634. [CrossRef]

55. Sun, H.Y.; Kim, K.P.; Bae, C.H.; Choi, A.J.; Paik, H.D.; Kim, I.H. Evaluation of *Weissella cibaria* JW15 probiotic derived from fermented Korean vegetable product in diet on performance characteristics in adult beagle dog. *Animals* 2019, 9, 581. [CrossRef] [PubMed]

56. Bastos, T.S.; De Lima, D.C.; Souza, C.M.M.; Maiorka, A.; De Oliveira, S.G.; Bittencourt, L.C.; Félix, A.P. *Bacillus subtilis* and *Bacillus licheniformis* reduce faecal protein catabolites concentration and odour in dogs. *BMVC Vet. Res.* 2020, 16, 116. [CrossRef] [PubMed]

57. Bruni, N.; Martello, E.; Fusì, E.; Meineri, G.; Giardini, A. Study of faecal parameters and body condition in dogs with a diet supplemented with *Lactobacillus acidophilus* D2/CSL (CECT 4529). *Ital. J. Anim. Sci.* 2020, 19, 704–711. [CrossRef]

58. Strompfová, V.; Marcinňková, M.; Simonová, M.; Bogovic-Matijasić, B.; Lauková, A. Application of potential probiotic *Lactobacillus fermentum* AD1 strain in healthy dogs. *Anaerobe* 2006, 12, 75–79. [CrossRef]

59. Strompfová, V.; Lauková, A.; Gancarcíková, S. Effectivity of freeze-dried form of *Lactobacillus fermentum* AD1-CCM7421 in dogs. *Folia Microbiol.* 2012, 57, 347–350. [CrossRef]

60. Strompfová, V.; Kubášová, I.; Lauková, A. Health benefits observed after probiotic *Lactobacillus fermentum* CCM 7421 application in dogs. *Appl. Microbiol. Biotechnol.* 2017, 101, 6309–6319. [CrossRef]

61. Benyacoub, J.; Czarnecki-Maulden, G.L.; Cavadini, C.; Sauthier, T.; Anderson, R.E.; Schiffirin, E.J.; Von der Weid, T. Supplementation of food with *Bifidobacterium longum* strain SF68 on serum cobalamin and folate concentrations in healthy dogs. *BMC Vet. Res.* 2015, 11, 2618–2629. [CrossRef] [PubMed]

62. Delucchi, L.; Fraga, M.; Perelmutter, K.; Cella, C.D.; Zunino, P. Effect of native *Lactobacillus murinus* LBp2 administration on total fecal IgA in healthy dogs. *Can. J. Vet. Res.* 2018, 76, 153–155.

63. Kumar, S.; Pattanaik, A.K.; Sharma, S.; Jadhav, S.E.; Dutta, N.; Kumar, A. Probiotic potential of a *Lactobacillus* bacterium of canine faecal-origin and its impact on select gut health indices and immune response of dogs. *Probiotics Antimicrob. Proteins* 2017, 9, 262–277. [CrossRef]

64. Lippi, I.; Perondi, F.; Ceccherini, G.; Marchetti, V.; Guidi, G. Effects of probiotic VSL#3 on glomerular filtration rate in dogs affected by chronic kidney disease: A pilot study. *Can. Vet. J.* 2017, 58, 1301–1305. [CrossRef]

65. Kim, H.; Rather, I.A.; Kim, H.; Kim, S.; Kim, T.; Jang, J.; Seo, J.; Lim, J.; Park, Y.H. A double-blind, placebo controlled-trial of a probiotic strain *Lactobacillus sakei* probio-65 for the prevention of canine atopic dermatitis. *J. Microbiol. Biotechnol.* 2019, 25, 1966–1969. [CrossRef] [PubMed]

66. Lee, K.; Yun, T.; Ham, J.; Lee, W.; Kang, J.; Yang, M.; Kang, B. Clinical trial of oral administration of *Bifidobacterium longum* in dogs with atopic dermatitis. *Korean J. Vet. Res.* 2020, 60, 19–24. [CrossRef]

67. D’Angelo, S.; Fracassi, F.; Bresciani, F.; Galuppi, R.; Diana, A.; Linta, N.; Bettini, G.; Morini, M.; Pietra, M. Effect of *Saccharomyces boulardii* in dogs with chronic enteropathies: Double-blinded, placebo-controlled study. *Vet. Rec.* 2018, 182, 258. [CrossRef]

68. Schmitz, S.; Werling, D.; Allesspach, K. Effects of ex-vivo and in-vivo treatment with probiotics on the inflammasome in dogs with chronic enteropathy. *PLoS ONE* 2015, 10, e0120779. [CrossRef]

69. Rossi, G.; Penco, G.; Caldin, M.; Piccionello, A.P.; Steiner, J.M.; Cohen, N.D.; Jergens, A.E.; Suchodolski, J.S. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. *PLoS ONE* 2014, 9, e94699.

70. Xu, H.; Zhao, F.; Hou, Q.; Huang, W.; Liu, Y.; Zhang, H.; Sun, Z. Metagenomic analysis revealed beneficial effects of probiotics in improving the composition and function of the gut microbiota in dogs with diarrhea. *Food Funct.* 2019, 10, 2618–2629. [CrossRef] [PubMed]

71. Delucchi, L.; Fraga, M.; Zunino, P. Effect of the probiotic *Lactobacillus murinus* lbP2 on clinical parameters of dogs with distemper-associated diarrhea. *Can. J. Vet. Res.* 2017, 81, 118–121. [PubMed]
72. Fernández, L.; Martínez, R.; Pérez, M.; Arroyo, R.; Rodríguez, J.M. Characterization of Lactobacillus rhamnosus MP01 and Lactobacillus plantarum MP02 and assessment of their potential for the prevention of gastrointestinal infections in an experimental canine model. *Front. Microbiol.* 2019, 10, 1117. [CrossRef]

73. Abd El-Razik, K.A.; Ibrahim, E.S.; Younes, A.M.; Arafah, A.A.; Abuelnaga, A.S.M.; Hedia, R.H. *Enterococcus faecium* isolated from healthy dogs for potential use as probiotics. *Bulg. J. Vet. Med.* 2020, 23, 197–205. [CrossRef]

74. Kubasová, I.; Lauková, A.; Harmárová, L.; Pristaš, P.; Strompfová, V. Evaluation of enterococci for potential probiotic utilization in dogs. *Folia Microbiol.* 2019, 64, 177–187. [CrossRef]

75. Ibs, K.H.; Rink, L. Zinc-altered immune function. *J. Nutr.* 2005, 133, 1452S–1456S. [CrossRef] [PubMed]

76. Schulthess, J.; Pandey, S.; Capitani, M.; Rue-Albrecht, K.C.; Arnold, I.; Franchini, F.; Chomka, A.; Iloitt, N.E.; Johnston, D.G.W.; Pires, E.; et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. *Immunity* 2019, 50, 432–445.e7. [CrossRef]

77. Bobeck, E.A. Nutrition and health: Companion animal applications: Functional nutrition in livestock and companion animals to modulate the immune response. *J. Anim. Sci.* 2020, 98, skaa035. [CrossRef]

78. Kandil, O.M.; Abou-Zeina, H.A. Effect of parenteral vitamin E and selenium supplementation on immune status of dogs vaccinated with subunit and somatic antigens against *Taenia hydatigena*. *Egypt. J. Soc. Parasitol.* 2005, 35, 537–550.

79. Singh, S.K.; Dimri, U.; Saxena, S.K.; Jadhav, R.K. Therapeutic management of canine atopic dermatitis by combination of pentoxifylline and PUFAs. *J. Vet. Pharmacol. Ther.* 2010, 33, 495–498. [CrossRef] [PubMed]

80. Rossi, M.; Amaretti, A.; Raimondi, S. Folate production by probiotic bacteria. *PLoS ONE* 2013, 8, e51907. [CrossRef] [PubMed]

81. Hosomi, K.; Kunisawa, J. The specific roles of vitamins in the regulation of immunosurveillance and maintenance of immunologic homeostasis in the gut. *Immune Netw.* 2017, 17, 13–19. [CrossRef]

82. Ruaux, C.G. Cobalamin in companion animals: Diagnostic marker, deficiency states and therapeutic implications. *Vet. J.* 2013, 196, 145–152. [CrossRef] [PubMed]

83. Rutgers, H.C.; Batt, R.M.; Elwood, C.M.; Lamport, A. Small intestinal bacterial overgrowth in dogs with chronic intestinal disease. *J. Am. Vet. Med. Assoc.* 1995, 206, 187–193.

84. Allenspach, K.; Wieland, B.; Gröne, A.; Gaschen, F. Chronic enteropathies in dogs: Evaluation of risk factors for negative outcome. *J. Vet. Intern. Med.* 2007, 21, 700–708. [CrossRef]

85. Toresson, L.; Steiner, J.M.; Suchodolski, J.S.; Spillmann, T. Oral Cobalamin Supplementation in Dogs with Chronic Enteropathies and Hypocobalaminemia. *J. Vet. Intern. Med.* 2016, 30, 101–107. [CrossRef]

86. Berghoff, N.; Parnell, N.K.; Hill, S.L.; Suchodolski, J.S.; Steiner, J.M. Serum cobalamin and methylmalonic acid concentrations in dogs with chronic gastrointestinal disease. *Am. J. Vet. Res.* 2013, 74, 84–89. [CrossRef]

87. Taranto, M.P.; Vera, J.L.; Hugenholtz, J.; De Valdez, G.F.; Sesma, F. *Lactobacillus reuteri* CRL1098 produces cobalamin. *J. Bacteriol.* 2003, 185, 5643–5647. [CrossRef]

88. Schauf, S.; de la Fuente, G.; Newbold, C.J.; Salas-Mani, A.; Torre, C.; Abeica, L.; Castrillo, C. Effect of dietary fat to starch content of nutrition on the gastrointestinal microbiome of cats and dogs: Impact on health and disease. *Front. Microbiol.* 2015, 6, 1849–1864. [CrossRef] [PubMed]

89. Swanson, K.S.; Grieshop, C.M.; Flickinger, E.A.; Bauer, L.L.; Chow, J.; Wolf, B.W.; Garleb, K.A.; Fahey, G.C., Jr. Fructooligosaccharides and *Lactobacillus acidophilus* modify gut microbial populations, total tract nutrient digestibilities and fecal protein catabolite concentrations in healthy adult dogs. *J. Nutr.* 2012, 132, 3721–3731. [CrossRef]

90. Kamath, P.S.; Hoepfner, M.T.; Phillips, S.F. Short-chain fatty acids stimulate motility of the canine ileum. *Am. J. Physiol.* 1987, 253 Pt 1, 427–433. [CrossRef]

91. Suchodolski, J.S. Diagnosis and interpretation of intestinal dysbiosis in dogs and cats. *Vet. J.* 2016, 215, 30–37. [CrossRef]

92. Suchodolski, J.S.; Markel, M.E.; Garcia-Mazcorro, J.F.; Unterer, S.; Heilmann, R.M.; Dowd, S.E.; Kachroo, P.; Ivanov, I.; Minamoto, Y.; Dillman, E.M.; et al. The fecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease. *PLoS ONE* 2012, 7, e51907. [CrossRef] [PubMed]

93. Minamoto, Y.; Minamoto, T.; Ihara, A.; Sattasathuchana, P.; Buono, A.; Rangachari, VR.; McNeeley, I.H.; Lidbury, J.; Steiner, J.M.; Suchodolski, J.S. Fecal short-chain fatty acid concentrations and dysbiosis in dogs with chronic enteropathy. *J. Vet. Intern. Med.* 2019, 33, 1608–1618. [CrossRef] [PubMed]

94. Guard, B.C.; Barr, J.W.; Reddivari, L.; Klemashevich, C.; Jayaraman, A.; Steiner, J.M.; Vanamala, J.; Suchodolski, J.S. Characterization of microbial dysbiosis and metabolomic changes in dogs with acute diarrhea. *PLoS ONE* 2015, 10, e0127259. [CrossRef]

95. Gagné, J.W.; Wakschlag, L.J.; Simpson, K.W.; Dowd, S.E.; Latchman, S.; Brown, D.A.; Brown, K.; Swanson, K.S.; Fahey, G.C., Jr. Effects of a symbiotic on fecal quality, short-chain fatty acid production, and the microbiome of healthy sled dogs. *BMC Vet. Res.* 2013, 9, 246. [CrossRef]

96. Jensen, A.P.; Bjornvad, C.R. Clinical effect of probiotics in prevention or treatment of gastrointestinal disease in dogs: A systematic review. *J. Vet. Intern. Med.* 2019, 33, 1849–1864. [CrossRef] [PubMed]

97. Schmitz, S.S. Value of probiotics in canine and feline gastroenterology. *Vet. Clin. N. Am. Small Anim. Pract.* 2021, 51, 171–217. [CrossRef] [PubMed]

98. Wernimont, S.M.; Radosевич, J.; Jackson, M.I.; Ephrain, E.; Badri, D.V.; MacLeay, J.M.; Jewell, D.E.; Suchodolski, J.S. The effects of nutrition on the gastrointestinal microbiome of cats and dogs: Impact on health and disease. *Front. Microbiol.* 2020, 11, 1266. [CrossRef] [PubMed]